유전체학 및 생명과학 컴퓨팅용 PIM : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the PIM for genomics and life science computing market size is projected to expand from USD 0.19 billion in 2025 and USD 0.25 billion in 2026 to USD 1.15 billion by 2031, registering a CAGR of 35.81% between 2026 and 2031.

This report is Segmented by Deployment Type (Cloud-Based, On-Premises, and Hybrid), Component (Hardware, and More), End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and More), Application (Sequence Alignment and Mapping, Variant Calling and Interpretation, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global PIM For Genomics and Life Science Computing Market Trends and Insights

AI-Driven Genomic Data Curation and Variant Interpretation

Artificial intelligence is changing the role of the PIM in the genomics and life science computing market from passive storage to active curation and interpretation. DNAnexus expanded this shift in May 2026, launching Omics Data Agent for no-code cohort creation and longitudinal queries, along with an AutoML Assistant that reduced model prototyping time by up to 80%. Illumina moved in the same direction in 2026 when DRAGEN v4.5 extended machine learning support for structural variant calling across germline and somatic use cases and added support for 5-base multiomic analyses. A 2026 study in the Journal of Translational Medicine showed that AI-assisted genomic analysis can combine phenotype standardization, pathogenicity ranking, and structured reporting in a traceable workflow for rare-disease diagnosis. These developments matter because curated evidence becomes easier to reuse once it is linked to consistent metadata, reporting logic, and version control. For the PIM for genomics and life science computing market, that means AI curation is moving from a premium feature to a core buying requirement for labs, biopharma teams, and regulated clinical users.

Rising Need For Interoperable Data Governance Across LIMS, EHR, and PIM Stacks

Interoperability is becoming a central demand in the PIM for genomics and life science computing market because laboratories, clinical systems, and product data environments now need shared governance rather than simple file exchange. QIAGEN Digital Insights showed this need in its November 2025 QCI Interpret update, which expanded expert curation coverage to around 1,100 genes and added multilingual reporting for global clinical genomics operations. Illumina's Emedgene software also integrates with LIMS, EHR, and other IT systems while maintaining a lab-curated repository that can populate interpretation templates in a controlled way. ISO/TS 21405:2026 adds another layer by establishing a formal framework for IDMP ontology development and semantically interoperable medicinal product data. This keeps interoperability from being a one-time integration project, since metadata models, reporting structures, and governance rules have to remain aligned as systems change. The PIM for genomics and life science computing market is therefore benefiting from demand for platforms that can manage data context across research, clinical, and regulatory environments without breaking auditability.

High Integration Cost with Legacy Life Science Systems

Legacy life science systems' slow adoption in the PIM for genomics and life science computing market because new tools must fit into validated environments that already support regulated work. Boehringer Ingelheim's One Medicine Platform, launched with Veeva in March 2025, connected clinical, regulatory, and quality data across its global R&D organization, which shows how broad these transformation programs need to be before value can be realized. Illumina's Emedgene material also highlights the number of interfaces involved, as the software connects to LIMS, EHR, and other IT systems while keeping interpretation workflows secure and structured. DNAnexus frames Trusted Regulatory Spaces around validated cloud collaboration, indicating that vendors now have to package compliance support with the platform itself. This increases the time, planning, and service burden associated with each rollout, especially when organizations are replacing long-standing workflows rather than adding isolated point tools. Vendors that reduce implementation friction are therefore in a stronger position as buyers compare migration effort against near-term productivity gains in the PIM for genomics and life science computing market.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Pressure for Audit-Ready Traceability in Clinical and Product Data
2. Increasing Demand for Cloud-Native Collaboration Across Distributed Research Networks
3. Data Privacy, Sovereignty, and Compliance Complexity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

On-premises deployment accounted for 61.13% of the PIM market share in genomics and life science computing in 2025, reflecting the weight of validated environments and stricter control expectations in regulated settings. That lead is tied to long-standing GxP practices, internal review routines, and the need to keep sensitive scientific records inside tightly managed infrastructures. Many buyers still view local control as the safer option, even though compliance, traceability, and data-handling policies have been built over several years. The segment also benefits from the fact that legacy LIMS, quality systems, and clinical applications are often easier to preserve than to replace in a single step. This keeps on-premises strong in the current revenue mix of the PIM for genomics and life science computing market, even as deployment preferences start to change.

Cloud-based deployment is projected to expand at a 36.48% CAGR through 2031, which makes it the fastest-growing deployment model in the PIM for genomics and life science computing market. DNAnexus's May 2026 launch of Omics Data Catalog and Omics Data Agent shows how cloud platforms are being built around governed discovery, reusable metadata, and direct AI interaction. Trusted Regulatory Spaces adds to that case by showing that regulated collaboration, audit support, and cloud access can now be combined in one controlled environment. Hybrid deployment is emerging as a practical middle path because organizations can keep sensitive records in existing local systems while running broader analytics and collaboration in the cloud. Over time, the PIM for genomics and life science computing market is likely to see cloud and hybrid models gain ground as validation playbooks improve and more buyers get comfortable with continuous platform updates.

Hardware accounted for 78.62% of the 2025 revenue base, which shows how much spending in the PIM for genomics and life science computing market has been tied to sequencers, high-performance computing assets, storage, and related infrastructure. That pattern reflects the heavy technical burden of next-generation sequencing, alignment, and high-volume data movement in production environments. Illumina's 2026 product activity supports this view, with TruPath Genome, distributed whole-genome sequencing for MRD research, and fireflyGO all pointing to continued investment in data generation and lab throughput. Hardware remains essential because no governance layer can create value if raw sequencing, compute performance, and storage reliability are weak. This means the installed hardware base still anchors a large part of the current structure of the PIM for genomics and life science computing market.

Software is projected to grow at a 36.42% CAGR, and that pace shows where differentiation is moving in the PIM for genomics and life science computing market. Illumina's DRAGEN v4.5 demonstrates this shift because the value is increasingly tied to better calling, broader assay support, and faster interpretation rather than to the instrument alone. DNAnexus has made the same point from a different angle by adding conversational search, metadata cataloging, and AutoML support directly into its governed platform. Services remain smaller in share, but they stay commercially important because integration, validation, and workflow setup still shape how quickly customers can use the software layer. In the PIM for genomics and life science computing industry, the center of value is gradually shifting from equipment ownership toward software intelligence and managed data orchestration.

Complete Report Scope:

• By Deployment Type
  • Cloud-Based
  • On-Premises
  • Hybrid
• By Component
  • Hardware
  • Software
  • Services
• By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Hospitals and Clinical Laboratories
  • Contract Research Organizations
  • Other End Users
• By Application
  • Sequence Alignment and Mapping
  • Variant Calling and Interpretation
  • Multi-Omics Analysis
  • Clinical Genomics
  • Drug Discovery and Target Identification
  • Population Genomics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Taiwan
    • India
    • Rest of Asia-Pacific
  • South America
  • Middle East and Africa

Geography Analysis

North America held 46.67% of the PIM for the genomics and life science computing market in 2025, maintaining its position as the leading regional block. The region benefits from dense biotech and pharma clusters in the United States, especially in Massachusetts, California, and North Carolina, where research intensity and commercialization activity support faster platform adoption. Illumina's February 2026 TruPath Genome launch, which had over 30 early-access customers including Broad Clinical Labs, GeneDx, Rady Children's Hospital, and Baylor College of Medicine, reflects the depth of active genomics deployment in the region. Canada and Mexico add support through research networks and service delivery capacity, even though the United States remains the core demand center in the PIM for genomics and life science computing market. Europe remains the second-largest geography, supported by strong demand in Germany, the United Kingdom, and France, as well as by tighter governance expectations shaped by the EHDS and federated data-sharing models.

Asia-Pacific is projected to grow at a 36.73% CAGR through 2031, making it the fastest-growing geography in the PIM for genomics and life science computing market. The regional rise is supported by large national genomics programs, faster biopharma expansion, and growing investment in compute and cloud capacity for life science work. China's 1,000 Chinese Pangenome project, reported in Nature in 2026, generated 1,116 diploid genome assemblies and an imputation reference panel, which shows the scale of governed data infrastructure now being created in the region. Japan and India also strengthen regional demand through regulatory modernization, local biopharma expansion, and broader interest in precision medicine workflows. This makes Asia-Pacific the clearest growth engine for the PIM for genomics and life science computing market outside North America.

South America and the Middle East and Africa remain smaller in current size, but both regions are gaining relevance as global sponsors extend clinical programs and precision medicine infrastructure into new locations. Brazil stands out in South America because public health genomics activity is helping build a more durable base for data management needs. Saudi Arabia and the United Arab Emirates are also raising regional visibility through broader healthcare diversification and precision medicine investment plans. Across both regions, the PIM for genomics and life science computing market is likely to expand first through collaborative projects, clinical trial infrastructure, and cross-border governance needs rather than through immediate large-scale platform replacement.

1. Illumina, Inc.
2. Thermo Fisher Scientific Inc.
3. QIAGEN N.V.
4. DNAnexus, Inc.
5. SOPHiA GENETICS SA
6. IBM Corporation
7. Oracle Corporation
8. SAP SE
9. Informatica LLC
10. Stibo Systems A/S
11. inriver AB
12. Syndigo LLC
13. Akeneo SAS
14. Contentserv AG
15. Pimcore GmbH
16. Salsify, Inc.
17. Veeva Systems Inc.
18. Benchling, Inc.
19. Fabric Genomics, Inc.
20. Geneva Bioinformatics, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions And Market Definition
• 1.2 Scope Of The Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 AI-Driven Genomic Data Curation and Variant Interpretation
  • 4.2.2 Rising Need for Interoperable Data Governance Across LIMS, EHR, and PIM Stacks
  • 4.2.3 Regulatory Pressure for Audit-Ready Traceability in Clinical and Product Data
  • 4.2.4 Increasing Demand for Cloud-Native Collaboration Across Distributed Research Networks
  • 4.2.5 Expansion of Multi-Omics and Precision Medicine Workflows
  • 4.2.6 Data Standardization and Metadata Enrichment at Scale
• 4.3 Market Restraints
  • 4.3.1 High Integration Cost with Legacy Life Science Systems
  • 4.3.2 Data Privacy, Sovereignty, and Compliance Complexity
  • 4.3.3 Fragmented Scientific Data Models and Workflow Incompatibility
  • 4.3.4 Limited In-House Bioinformatics and Data Governance Skills
• 4.4 Industry Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Buyers
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry
• 4.8 Impact of Macroeconomic Factors on the Market

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Deployment Type
  • 5.1.1 Cloud-Based
  • 5.1.2 On-Premises
  • 5.1.3 Hybrid
• 5.2 By Component
  • 5.2.1 Hardware
  • 5.2.2 Software
  • 5.2.3 Services
• 5.3 By End User
  • 5.3.1 Pharmaceutical and Biotechnology Companies
  • 5.3.2 Academic and Research Institutes
  • 5.3.3 Hospitals and Clinical Laboratories
  • 5.3.4 Contract Research Organizations
  • 5.3.5 Other End Users
• 5.4 By Application
  • 5.4.1 Sequence Alignment and Mapping
  • 5.4.2 Variant Calling and Interpretation
  • 5.4.3 Multi-Omics Analysis
  • 5.4.4 Clinical Genomics
  • 5.4.5 Drug Discovery and Target Identification
  • 5.4.6 Population Genomics
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 South Korea
    • 5.5.3.4 Taiwan
    • 5.5.3.5 India
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
  • 5.5.5 Middle East and Africa

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.4.1 Illumina, Inc.
  • 6.4.2 Thermo Fisher Scientific Inc.
  • 6.4.3 QIAGEN N.V.
  • 6.4.4 DNAnexus, Inc.
  • 6.4.5 SOPHiA GENETICS SA
  • 6.4.6 IBM Corporation
  • 6.4.7 Oracle Corporation
  • 6.4.8 SAP SE
  • 6.4.9 Informatica LLC
  • 6.4.10 Stibo Systems A/S
  • 6.4.11 inriver AB
  • 6.4.12 Syndigo LLC
  • 6.4.13 Akeneo SAS
  • 6.4.14 Contentserv AG
  • 6.4.15 Pimcore GmbH
  • 6.4.16 Salsify, Inc.
  • 6.4.17 Veeva Systems Inc.
  • 6.4.18 Benchling, Inc.
  • 6.4.19 Fabric Genomics, Inc.
  • 6.4.20 Geneva Bioinformatics, Inc.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment